{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:45:56Z","timestamp":1792755956145,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA224019"],"award-info":[{"award-number":["U54CA224019"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA262758"],"award-info":[{"award-number":["R01CA262758"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006668","name":"Oregon Health and Science University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018124","name":"Silver Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.xcrm.2025.102526","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:46:29Z","timestamp":1767023189000},"page":"102526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["CDK4\/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3273-0246","authenticated-orcid":false,"given":"Melissa L.","family":"Stewart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Watanabe-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Kenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Thiel-Klare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Kaempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bottomly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer N.","family":"Saultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon K.","family":"McWeeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102526_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.xcrm.2025.102526_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/2643-3230.BCD-23-0014","article-title":"Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy","volume":"4","author":"Eide","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102526_bib4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102526_bib5","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/bloodadvances.2021006307","article-title":"Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia","volume":"6","author":"Kurtz","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2025.102526_bib6","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanmaki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanmaki","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102526_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102526_bib9","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","article-title":"A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy","volume":"13","author":"Pei","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102526_bib10","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","article-title":"A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia","volume":"28","author":"Zeng","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102526_bib11","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3324\/haematol.2019.217414","article-title":"Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types","volume":"105","author":"Majumder","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102526_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s43018-020-0103-x","article-title":"Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia","volume":"1","author":"Zhang","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102526_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.2024024968","article-title":"Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial","volume":"145","author":"Kytola","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib14","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1158\/1078-0432.CCR-16-0493","article-title":"FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer","volume":"22","author":"Walker","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102526_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc2602","article-title":"Cell cycle, CDKs and cancer: a changing paradigm","volume":"9","author":"Malumbres","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102526_bib16","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From Discovery to Therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102526_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16061091","article-title":"Venetoclax Resistance in Acute Myeloid Leukemia","volume":"16","author":"Garciaz","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102526_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102526_bib19","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","article-title":"Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax","volume":"13","author":"Waclawiczek","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102526_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","article-title":"RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax","volume":"636","author":"Sango","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102526_bib21","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib22","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","article-title":"Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naive Acute Myeloid Leukemia","volume":"28","author":"Konopleva","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102526_bib23","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","article-title":"The Reactome Pathway Knowledgebase 2024","volume":"52","author":"Milacic","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102526_bib24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","article-title":"A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia","volume":"17","author":"Tzelepis","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102526_bib25","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102526_bib26","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity","volume":"176","author":"van Galen","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102526_bib27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nmeth.1314","article-title":"SUnSET, a nonradioactive method to monitor protein synthesis","volume":"6","author":"Schmidt","year":"2009","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102526_bib28","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.4933","article-title":"SUrface SEnsing of Translation (SUnSET), a Method Based on Western Blot Assessing Protein Synthesis Rates in vitro","volume":"14","author":"Piecyk","year":"2024","journal-title":"Bio. Protoc."},{"key":"10.1016\/j.xcrm.2025.102526_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccr.2010.01.021","article-title":"Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E","volume":"17","author":"Hsieh","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102526_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.068","article-title":"Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1","volume":"31","author":"Romero-Pozuelo","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2025.102526_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102526_bib33","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors' current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2025.102526_bib34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/oncolo\/oyac089","article-title":"Real-World Experience with CDK4\/6 Inhibitors for Metastatic HR+\/HER2- Breast Cancer at a Single Cancer Center","volume":"27","author":"Knudsen","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2025.102526_bib35","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41467-025-56096-2","article-title":"Lerociclib plus fulvestrant in patients with HR+\/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102526_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143456","article-title":"Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies","volume":"14","author":"Griffioen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102526_bib37","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.54954","article-title":"MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation","volume":"9","author":"Arai","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2025.102526_bib38","doi-asserted-by":"crossref","first-page":"6891","DOI":"10.1038\/ncomms7891","article-title":"The NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrest","volume":"6","author":"Haschka","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102526_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100677","article-title":"IKZF1 alterations in acute lymphoblastic leukemia: The good, the bad and the ugly","volume":"44","author":"Vairy","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.xcrm.2025.102526_bib40","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41375-023-02061-1","article-title":"Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia","volume":"37","author":"Eckardt","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2025.102526_bib41","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1309","article-title":"Identification of IKZF1 genetic mutations as new molecular subtypes in acute myeloid leukaemia","volume":"13","author":"Wang","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102526_bib42","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Maiti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2025.102526_bib43","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-020-00972-5","article-title":"The specific distribution pattern of IKZF1 mutation in acute myeloid leukemia","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102526_bib44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2025.102526_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11111727","article-title":"AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma","volume":"11","author":"Yan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2025.102526_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113527","article-title":"Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia","volume":"153","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.xcrm.2025.102526_bib47","doi-asserted-by":"crossref","first-page":"9755","DOI":"10.1038\/s41467-024-53874-2","article-title":"Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer","volume":"15","author":"Chatterjee","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102526_bib48","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2015-05-645069","article-title":"Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas","volume":"127","author":"Culjkovic-Kraljacic","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib49","article-title":"Research Brief: Translation Initiation Represents an Acute Myeloid Leukemia Cell Vulnerability That Can Be Co-Targeted With BCL-2 Inhibition","author":"Lee","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2025.102526_bib50","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood.2024024837","article-title":"A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia","volume":"145","author":"Liu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib51","doi-asserted-by":"crossref","first-page":"653","DOI":"10.18632\/oncotarget.28440","article-title":"Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability","volume":"14","author":"Tantawy","year":"2023","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102526_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100672","article-title":"Targeting MCL-1 in hematologic malignancies: Rationale and progress","volume":"44","author":"Wei","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.xcrm.2025.102526_bib53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-023-00380-z","article-title":"Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients","volume":"3","author":"Yuda","year":"2023","journal-title":"Commun. Med."},{"key":"10.1016\/j.xcrm.2025.102526_bib54","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","article-title":"Targeting CDK4 and CDK6 in cancer.","volume":"22","author":"Goel","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102526_bib55","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xcrm.2025.102526_bib56","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.2019000813","article-title":"IKZF1 deletions in pediatric acute lymphoblastic leukemia: still a poor prognostic marker?","volume":"135","author":"Stanulla","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib57","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2217\/fon-2021-1450","article-title":"PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer","volume":"18","author":"Muttiah","year":"2022","journal-title":"Future Oncol."},{"key":"10.1016\/j.xcrm.2025.102526_bib58","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00280-024-04642-y","article-title":"Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory\/relapsed therapy-related acute myeloid leukemia","volume":"94","author":"Qu","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.102526_bib59","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fonc.2019.01205","article-title":"Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia","volume":"9","author":"Tibes","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2025.102526_bib60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","article-title":"CDK9 inhibitors in acute myeloid leukemia","volume":"37","author":"Boffo","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102526_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15916","article-title":"CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers","volume":"8","author":"Vijayaraghavan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102526_bib62","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102526_bib63","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41419-021-04285-4","article-title":"Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells","volume":"12","author":"Ludwig","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2025.102526_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102526_bib65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adn9832","article-title":"Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder","volume":"17","author":"Mohammadhosseini","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102526_bib66","doi-asserted-by":"crossref","first-page":"E7554","DOI":"10.1073\/pnas.1703094114","article-title":"Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies","volume":"114","author":"Kurtz","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102526_bib67","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102526_bib68","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1371\/journal.pgen.0030161","article-title":"Capturing heterogeneity in gene expression studies by surrogate variable analysis","volume":"3","author":"Leek","year":"2007","journal-title":"PLoS Genet."},{"key":"10.1016\/j.xcrm.2025.102526_bib69","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102526_bib70","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102526_bib71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Benjamini","year":"1995","journal-title":"Journal of the Royal Statistical Society. Series B (Methodological)"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125005993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:50:39Z","timestamp":1776207039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125005993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666379125005993"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102526","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CDK4\/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102526"}}